cc-42344
Small moleculeexperimental
Clinical trial activity
2 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Feb 11, 2022 (NCT05202379)
Timeline
Indications
Studied for
Mechanism of action
- Influenza A virusANTAGONIST
Influenza A virus antagonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06160531 | Phase 2 | Nov 25, 2023 | Cocrystal Pharma, Inc., hVIVO Services Limited |
| NCT05202379 | Phase 1 | Feb 11, 2022 | Cocrystal Pharma Australia Pty Ltd., Cocrystal Pharma, Inc., Linear Clinical Research |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Cocrystal Pharma, Inc. | For profit | 2 | 2 | 2 | 2022 |
| Cocrystal Pharma Australia Pty Ltd. | For profit | 1 | 0 | 1 | 2022 |
| hVIVO Services Limited | For profit | 1 | 0 | 1 | 2023 |
| Linear Clinical Research | For profit | 1 | 0 | 1 | 2022 |
4 organizations
Page 1 / 1